Over two-thirds of women with breast cancer have positive tumors for hormone receptors, and these patients undergo treatment with endocrine therapy, tamoxifen being the most widely used agent. Despite being very effective in breast cancer treatment, tamoxifen is associated with side effects that include cognitive impairments. However, the specific aspects and mechanisms underlying these impairments remain to be characterized. Here, we have investigated the effects of tamoxifen and interaction with estrogen receptors on formation of memory for inhibitory avoidance conditioning in female rats. In the first experiment, Wistar female rats received a single oral dose of tamoxifen (1, 3, or 10mg/kg) or saline by gavage immediately after training and were tested for memory consolidation 24h after training. In the second experiment, rats received a single dose of 1mg/kg tamoxifen or saline by gavage 3h after training and were tested 24h after training for memory consolidation. In the third experiment, rats received a subcutaneous injection with estrogen receptor α agonist or estrogen receptor beta agonist 30min before the training. After training, rats received a single oral dose of tamoxifen 1mg/kg or saline and were tested 24h after training. In the fourth experiment, rats were trained and tested 24h later. Immediately after test, rats received a single dose of tamoxifen (1mg/kg) or saline by gavage and were given four additional daily test trials followed by a re-instatement. Tamoxifen at 1mg/kg impaired memory consolidation when given immediately after training and the estrogen receptor alpha agonist improved the tamoxifen-related memory impairment. Moreover, tamoxifen impairs memory consolidation of the test. These findings indicate that estrogen receptors regulate the early phase of memory consolidation and the effects of tamoxifen on memory consolidation.
Read full abstract